Citigroup Inc Xencor Inc Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Xencor Inc stock. As of the latest transaction made, Citigroup Inc holds 229,111 shares of XNCR stock, worth $4.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

229,111

Previous 82,157 178.87%

Holding current value

$4.34 Million

Previous $1.74 Million 190.71%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$18.65 - $26.52 $2.74 Million - $3.9 Million	146,954 Added 178.87%	229,111 $5.07 Million
Q4 2023 Feb 09, 2024	BUY	$16.53 - $21.42 $196,178 - $254,212	11,868 Added 16.88%	82,157 $1.74 Million
Q3 2023 Nov 09, 2023	SELL	$20.08 - $25.39 $142,106 - $179,685	-7,077 Reduced 9.15%	70,289 $1.42 Million
Q2 2023 Aug 10, 2023	SELL	$24.77 - $29.9 $1.32 Million - $1.6 Million	-53,400 Reduced 40.84%	77,366 $1.93 Million
Q1 2023 May 11, 2023	BUY	$25.95 - $36.95 $1.04 Million - $1.48 Million	40,080 Added 44.2%	130,766 $3.65 Million

Q4 2022 Feb 09, 2023	SELL	$24.79 - $30.86 $1.08 Million - $1.35 Million	-43,617 Reduced 32.48%	90,686 $2.36 Million
Q3 2022 Nov 10, 2022	BUY	$24.62 - $32.44 $900,279 - $1.19 Million	36,567 Added 37.41%	134,303 $3.49 Million
Q2 2022 Aug 10, 2022	BUY	$19.74 - $29.01 $601,556 - $884,050	30,474 Added 45.31%	97,736 $2.67 Million
Q1 2022 May 12, 2022	SELL	$26.68 - $41.63 $790,955 - $1.23 Million	-29,646 Reduced 30.59%	67,262 $1.8 Million
Q4 2021 Feb 10, 2022	BUY	$33.67 - $43.44 $1.01 Million - $1.3 Million	29,896 Added 44.61%	96,908 $3.89 Million
Q3 2021 Nov 10, 2021	BUY	$30.65 - $35.68 $2.05 Million - $2.39 Million	67,012 New	67,012 $2.19 Million

Others Institutions Holding XNCR

# of Institutions

203

Shares Held

64M

Call Options Held

2.2K

Put Options Held

1.3K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.13B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account